1. |
Penon D, Cito L, Giordano A. Novel findings about management of gastric cancer:a summary from 10th IGCC. World J Gastroenterol, 2014, 20(27):8986-8992.
|
2. |
Shen L, Shan YS, Hu HM, et al. Management of gastric cancer in Asia:resource-stratified guidelines. Lancet Oncol, 2013, 14(12):e535-e547.
|
3. |
Brenner MK, Gottschalk S, Leen AM, et al. Is cancer gene therapy an empty suit?. Lancet Oncol, 2013, 14(11):e447-e456.
|
4. |
周培华, 孙学军, 王燕, 等. 5HRE强化的肝癌靶向性自杀基因载体的构建.中国普外基础与临床杂志, 2007, 14(2):163-167.
|
5. |
孙学军, 卢乐, 禄韶英, 等. 5HRE联合P_(CEA)调节TSST-1/CD80TM重组基因表达的逆转录病毒载体的构建.细胞与分子免疫学杂志, 2009, 25(10):863-865.
|
6. |
药立波.医学分子生物学实验技术.第2版.北京:人民卫生出版社, 2011:353-355.
|
7. |
Vaupel P, Mayer A. Hypoxia in cancer:significance and impact on clinical outcome. Cancer Metastasis Rev, 2007, 26(2):225-239.
|
8. |
Keith B, Johnson RS, Simon MC. HIF1αand HIF2α:sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer, 2012, 12(1):9-22.
|
9. |
Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE, 2005, 2005(36):re12.
|
10. |
Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia, 2002, 4(1):40-48.
|
11. |
Harvey TJ, Hennig IM, Shnyder SD, et al. Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo. Cancer Gene Ther, 2011, 18(11):773-784.
|
12. |
贺赛, 郑见宝, 孙学军, 等. 5HRE增强子和hTERT启动子联合调控CDX2基因对人结肠癌细胞系LoVo增殖的抑制.中国肿瘤生物治疗杂志, 2014, 21(3):314-319.
|
13. |
Hammarström S. The carcinoembryonic antigen (CEA) family:structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol, 1999, 9(2):67-81.
|
14. |
Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer, 2012, 76(2):138-143.
|
15. |
Chen S, Feng XY, Li YF, et al. The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy. J Surg Oncol, 2013, 107(6):641-645.
|
16. |
Qiu Y, Peng GL, Liu QC, et al. Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD). Cancer Lett, 2012, 316(1):31-38.
|
17. |
Wang W, Sun X, Lu L, et al. Cytotoxicity of lymphocytes activated by superantigen toxic-shock-syndrome toxin-1 against colorectal cancer LoVo cells. Mol Cell Biochem, 2013, 376(1-2):1-9.
|
18. |
Nyati MK, Sreekumar A, Li S, et al. High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Res, 2002, 62(8):2337-2342.
|
19. |
Liu T, Zhang G, Chen YH, et al. Tissue specific expression of suicide genes delivered by nanoparticles inhibits gastric carcinoma growth. Cancer Biol Ther, 2006, 5(12):1683-1690.
|
20. |
Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet, 2000, 25(3):315-319.
|
21. |
Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci, 2007, 120(Pt 18):3163-3172.
|
22. |
Amin KS, Banerjee PP. The cellular functions of RASSF1A and its inactivation in prostate cancer. J Carcinog, 2012, 11(3):31-38.
|
23. |
Jung HY, Jung JS, Whang YM, et al. RASSF1A suppresses cell migration through inactivation of HDAC6 and increase of acetylatedα-Tubulin. Cancer Res Treat, 2013, 45(2):134-144.
|
24. |
De Sousa Abreu R, Penalva LO, Marcotte EM, et al. Global signatures of protein and mRNA expression levels. Mol Biosyst, 2009, 5(12):1512-1526.
|
25. |
Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet, 2012, 13(4):227-232.
|
26. |
Ardyanto TD, Osaki M, Nagahama Y, et al. Down-regulation of cobalt-induced HIF-1 alpha expression correlates with cell proliferation and apoptosis in human gastric carcinoma cells. Oncol Rep, 2008, 19(2):339-343.
|